Printer Friendly

Syndax and AstraZeneca partnering in immuno-oncology clinical trial.

Syndax (SNDX) announced a new clinical collaboration with AstraZeneca (AZN) to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1, in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor, across a variety of solid tumors. Under the terms of the agreement, Syndax and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types. Syndax expects to initiate a Phase Ib study in 1H18 to establish the safety and recommended dose regimen of SNDX-6352 in combination with durvalumab. Data from this study will enable both companies to sponsor, design and initiate subsequent Phase II studies aimed at exploring the safety and efficacy of the combination across a number of defined tumor types. Financial and other terms of the agreement were not disclosed.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 1, 2018
Previous Article:Neovasc receives German NUB Status 1 designation for Neovasc Reducer.
Next Article:ConocoPhillips signs deal to buy 22% interest in Western North Slope.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters